I Predicted It: Social Media Guidance Likely To Be Split Into Multiple Documents

"What had been envisioned as a massive, all-encompassing guidance on Internet promotion is being retooled as multiple guidances to address specific issues in the online realm," Tom Abrams, head of the Center for Drug Evaluation and Research's Division of Drug Marketing, Advertising and Communications (DDMAC) said during a panel discussion at the Drug Information Association's annual meeting in Washington, D.C., June 15. (Picked up from a "FDA Library Alert" email -- "DDMAC: Social Media Guidance Likely To Be Split Into Multiple Documents" -- I just received.)

Either I can see into the future, or FDA reads Pharma Marketing Blog and takes my advice. In November, 2009, I said "If FDA decides to bite off more than it can chew, it will take a long time to issue any guidance and whatever it comes up with will be out of date as soon as it is published. A much better approach would be to tackle a few issues at a time" (see "FDA Social Media Guidelines Best Done in Baby Steps").

More from "FDA Library Alert":
Abrams said the planned move from a single document covering all forms of online promotion -- such as social media, webpages and videos -- to multiple, targeted guidances will help future-proof DDMAC's oversight of the web. It would give DDMAC greater flexibility in the event that new technologies emerge to supplant today's online media.

"Technology is evolving so much, we don't want the guidance to become quickly outdated," Abrams explained.

He emphasized that this shift is not set in stone, but is simply the division's "current vision" for the guidance. "It could change at any time," he noted.

If the division does adopt this approach, the guidances will not be rolled out all at once, but over the course of time, Abrams said. He added that the first of these guidances will likely be released this year.

During the conference, Abrams also revealed that the Internet guidances likely would address specific issues or circumstances -- such as the posting of unprompted data on off-label use of a product or the question of responsibility when off-label information is posted on a third-party site -- rather than specific platforms -- such as websites or Twitter.

Abrams declined to give a complete breakdown of the guidance topics envisioned or the number of guidances expected under this approach.

For more details, see the August edition of the FDA Advertising and Promotion Manual.

Sex, Pharmaceuticals, and Selling Sickness: I'm Looking Forward to a Great Time In Amsterdam!


This October I will be in Amsterdam enjoying the sights and pleasures that city has to offer. But I am not planning to buy sex or to smoke pharmaceutical substances. I do plan, however, to attend and make a presentation at the Selling Sickness conference hosted by Healthy Skepticism (Netherlands), assisted by the Dutch Institute for Rational Use of Medicine and Healthy Skepticism (International). The sponsors include the Dutch Ministry of Health and the Dutch Health Care Inspectorate. You can find the program here.

I look forward to this conference because "Female sexual dysfunction will be used as a case study to explore problems with disease promotion as well as policy options." Ray Moynihan, journalist, co-author of the book "Selling Sickness: How The World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients" and author of "Sex, Lies & Pharmaceuticals," is a featured speaker.

In preparation for the conference, I am following closely the news about flibanserin, a new drug developed by the German pharma company Boehringer Ingelheim (BI) for "hypoactive sexual desire disorder" (HSDD) in pre-menopausal women. Today, an FDA advisory committee will meet to review this drug's application for marketing approval. BI must answer the question FDA always asks: is the drug safe and effective. The FDA’s own review, out yesterday, says the overall response rate in clinical trials isn't "particularly compelling," reports the WSJ Health Blog.

Perhaps an even more interesting question is whether or not hypoactive sexual desire disorder is a real medical condition. FDA does not consider that question when approving drugs. Whatever compound comes their way for which a drug company has clinical data, FDA's only duty is to consider if it is safe and effective for whatever "condition" it is designed to treat. A drug company is free to invent a medical condition and FDA can't say a word about that.

Do pharma companies "invent" medical conditions in order to sell drugs? Is hypoactive sexual desire disorder an "invented" medical condition?

One case where there is "smoking gun" evidence of a medical condition being invented by a pharma company is "overactive bladder," another condition affecting mostly women. "Pharmacia instrumental in creating new disease," said a marketing VP in the notes to his PowerPoint presentation made at an industry conference in October, 2002 (see Overactive Bladder: "Pharmacia instrumental in creating new disease" says Former VP).

My fellow blogger, Rich Myer, reviewed all the PR that BI is doing to create awareness of hypoactive sexual desire disorder: "In the last month, Boehringer has been trying to lay the consumer groundwork with a promotional campaign about women’s low libido, including a Web site, a Twitter feed, a Discovery Channel documentary and a publicity tour by Lisa Rinna, a soap opera star and former Playboy model, who describes herself as someone who has suffered from a disorder that Boehringer refers to as a form of 'female sexual dysfunction.'" In his post Rich quotes Dr. Adriane Fugh-Berman, an associate professor at Georgetown University’s medical school: "This is really a classic case of disease branding,” said Fugh-Berman. “The messages are aimed at medicalizing normal conditions, and also preying on the insecurity of both the clinician and the patient."

Oh, Oh, Rich! You are not in command of the facts. You should have read BI's "Key Facts on HSDD and Flibanserin". One fact cited is this: "HSDD is a medical condition – not simply 'low libido.'"

Anyway, this is sure to be a BIG topic for discussion at the Selling Sickness conference in Amsterdam. I wonder if people from BI will be there or invited to speak? Hope so.

FDA Sucker Punches Sepracor with Warning Letter After the Match Is Over!

On June 9, 2010, Carrie Newcomer, Regulatory Review Officer in FDA's Division of Drug Marketing, Advertising and Communications (DDMAC), sent a "warning" letter to Kathleen Grim, Executive Director, Regulatory Compliance at Sepracor Inc., about a Lunesta TV ad that Newcomer said "presents unsubstantiated claims, including unsubstantiated superiority claims."

The ad in question is the so-called "Boxing Bed" ad, which shows a sleepless woman tossing and turning in a bed that is also a boxing ring. Here's a panel from the storyboard that was submitted to the FDA on November 19, 2009, about the time the ad first ran on TV:
This ad was voted one of "The 10 Worst TV Ads of 2009" (see here).

In other words, the ad appeared way back in 2009 and the FDA is just now sending Sepracor a warning letter after having the storyboard in its possession for 7 months! Of course, the ad has run its course and Sepracor and Lunesta have long left the ring. But the FDA still went after them with this sucker punch.

What is FDA demanding? "DDMAC requests that Sepracor immediately cease the dissemination of violative promotional materials for Lunesta such as those described above. Please submit a written response to this letter on or before June 23, 2010, stating whether you intend to comply with this request..."

I imagine a grin on Ms. Grim's face as she sits in her office somewhere in Malborough, MA reading Newcomer's letter. "Yes," says Grim, "we'll cease airing that commercial three months ago and I will write this 'newcomer' a response as soon as I return from my vacation on the Cape. Meanwhile, I'll have my staff frame this letter to add to the collection hanging behind my desk."

BTW, while searching Google for this ad, I found an interesting Lunesta paid search ad as seen here:
This is the first time I have ever seen a drug ad that talks ONLY about side effects! I assure you that the ad linked to the official Lunesta Web site and NOT a lawyer's class action Web site. Perhaps Sepracor is trying to atone for running those infamous "badWords," which violated FDA regulations (see Lunesta, Google, and "bAdWords").

Are Docs Being Banished from Pharma's Garden of Eden?

"It is a breathtaking sweep to squash something that is really important to us, the science going on in the private sector," said Francis Collins, director of the National Institutes of Health, at a meeting in Bethesda, Md. At issue is a decision by the American Heart Association (AHA) to ban pharmaceutical industry employees from making medical education presentations later this year at the AHA's annual scientific sessions (see "Drug firms banished from medical talks").

"The policy is blood-curdling," said Keith Yamamoto, executive vice dean of the University of California, San Francisco School of Medicine. "This is conflict-of-interest considerations run amok."

Wow! It's as if physicians were banished from an Eden where they enjoyed the fruits of the tree of knowledge made accessible by the pharmaceutical industry. To some, it's a development of biblical proportions that deserves an appropriate image:


Before the drug industry advocates get their panties in a bundle over this, let's see exactly what the AHA says about the policy (find it here):
"In compliance with ACCME requirements, employees of a commercial interest entity cannot be the presenting author of the abstract. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. For our purposes, an employee is defined as someone who is directly working for the commercial interest as their primary employer and the commercial interest provides their primary source of income. A person acting as a contractor to a commercial interest, providing consultation, or other services secondary to their primary appointment at, for example, a university, would not be considered an employee."

"If the abstract is selected for presentation (oral or poster)," says AHA, "the employee of the commercial interest cannot present but must select another author."
What this means is that an abstract that is authored soley by a physician or physicians DIRECTLY employed full-time by a pharmaceutical company can be blocked. Otherwise, another, non-pharma employee author can make the presentation. There is almost always other non-pharma authors, including the physicians who ran the clinical studies being reported. Also, ghostwriters can make presentations, as indicated by this FAQ from AHA:
Q: I am the primary author of an abstract and designated as the presenter. I am currently employed by a home health agency. Can I still present my abstract?

A. Yes, the ACCME does not consider providers of clinical service directly to patients to be commercial interests.
IMHO, all the fuss over this AHA decision is unjustified as far as physician education is concerned. It may, however, be a blow to pharma research physicians who do all their clinical trials in-house without using independent physicians outside the firm. And that kind of "science" we can do without.